With more people turning to popular weight-loss medications, questions about potential side effects are increasing — and some consumers are exploring an Ozempic lawsuit.
Recent research, as Fox News Digital reports, has looked at how drugs like Ozempic, Wegovy, Mounjaro, and Zepbound may affect eye health in people with type 2 diabetes.
These medications, according to Cleveland Clinic, are part of a class called GLP-1 receptor agonists, which help manage diabetes and support weight loss by improving blood sugar control and reducing appetite. While they offer clear benefits, studies suggest there is a small risk of rare eye problems, making regular monitoring important.
Understanding The Risk
According to Fox News Digital, two studies published in the Journal of the American Medical Association (JAMA) followed more than 159,000 Americans with type 2 diabetes for two years.
The studies found a slight increase in cases of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden vision loss.
The outlet also states that out of all participants, 35 developed NAION compared to 19 in a control group. The researchers also reported 93 cases of “other optic nerve disorders.”
What The Experts Say
Medical professionals say the risk is very low, but monitoring eye health is important.
Dr. Sue Decotiis, a medical weight-loss specialist in New York City who did not participate in the research, spoke to Fox News Digital on the matter.
“NAION is a rare condition of the optic nerve that, although serious, has not really been shown to be increased by these studies,” she told the outlet. “We need more studies for certain.”
Meanwhile, Dr. Ashley Brissette, an eye specialist also located in New York City, described NAION to Fox News Digital as a rare but serious condition.
“From an ophthalmologic standpoint, these findings underscore the importance of baseline and follow-up eye examinations for patients starting GLP-1 therapy, especially those with pre-existing retinal or optic nerve risk factors,” she said.
Dr. Brissette also noted that although GLP-1 medications offer significant benefits for heart and metabolic health, patients should be informed about possible vision-related side effects, and any sudden vision changes should lead to an immediate visit to an eye specialist.
Ozempic Lawsuit Questions
As more people take these medications, questions about Ozempic lawsuits are surfacing, per Fox News Digital. Patients experiencing sudden vision changes may want to discuss next steps with their healthcare provider or a legal professional, especially if early warning signs were not communicated.
Novo Nordisk, the maker of Ozempic and Wegovy, according to the outlet, maintains that NAION is extremely rare and that clinical trial data do not show a direct link between their medications and the eye condition.
In a statement to Fox News Digital, Nordisk had this to say:
“Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously. NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels in the U.S.”
The statement continued with, “Novo Nordisk, on its part, has conducted an analysis across randomized controlled clinical trials with GLP-1 receptor agonists, including a blinded ophthalmologist evaluation to confirm NAION diagnoses. Our current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and NAION events.”
What Patients Should Do
If you’re starting GLP-1 treatment:
- Schedule an eye exam before beginning the medication.
- Keep up with regular follow-up exams.
- Seek immediate attention if you notice sudden changes in your vision.
While these medications can help manage diabetes and support heart health, its important to monitor eye health. Those experiencing unexpected vision problems many consider exploring an Ozempic lawsuit.
